^
    Apply
    Safety and Efficacy of OBX-115 in Advanced Solid Tumors (Agni-01) (NCT06060613)
    Phase 1/2
    Obsidian Therapeutics, Inc.
    Recruiting
    Last update posted :
    02/19/2025
    Initiation :
    10/25/2023
    Primary completion :
    10/30/2025
    Completion :
    10/30/2027
    PD-L1 • BRAF • PD-1
    |
    BRAF mutation • BRAF V600
    |
    cyclophosphamide • fludarabine IV • OBX-115